soul trial oral semaglutide cardiovascular outcomes trial results SOUL: Bests Usual Care in High-Risk Type 2 Diabetes Semaglutide and Cardiovascular in – Projected reduction in major adverse

doi: 10.1002/dmrr.3070 Summary Keywords GLP-1 receptor agonists, thyroid disorders, thyroid cancer, meta-analysis, randomized controlled trials Citation Hu W, Song R, Cheng R, Liu C, Guo R, Tang W, Zhang J, Zhao Q, Li X and Liu J (2022) Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials

Michelle Oravitz: I Dr

Example calculation: (10 20) 100 = 50 units

Many users experience reduced appetite and food intake on GLP-1 medications, which means they are also consuming less water from food sources

Most study referrals came from the Michael J Fox Foundation Trial Finder (45%) and Washington State PD Registry (42%), with health-care providers and friends contributing to the remaining referrals (13%)